Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

About Us

BoD

Renee Aguiar-Lucander

  - Director
No Image

 

Renee Aguiar-Lucander has been a director since November 2006. She is since February 2009 a partner in Omega Funds, a secondary fund focused on healthcare. Within  Omega, she  heads up the London office and is responsible for both private and quoted  healthcare portfolio companies. 

As such Mrs Aguiar-Lucander serves on the board of selected, privately held  Omega investments. Between 2005 and 2009 she was a partner in  the venture capital team of 3i Group plc, a leading private equity and venture capital firm with around USD 10 billion of assets under management, where she was a senior member of the European portfolio management team with a focus on healthcare assets. From 2000 to 2003  she was a Managing Director in corporate finance with Lehman Brothers, focusing primarily on the Technology, Media and Communications sectors, following which she worked as an advisor for private equity funds prior to joining 3i Group in January of 2005. Prior to joining Lehman Brothers in 1999, Ms. Aguiar-Lucander worked for Deutsche Bank and Alex. Brown&Sons, both in the US and in Europe focusing on M&A and private/public capital-raising for growth companies. Ms. Aguiar-Lucander has a bachelor-s degree in finance from Stockhom School of Economics and a master-s degree in business administration from INSEAD. She is of Swedish nationality.

Permanent management and consultancy functions for Swiss and foreign interest groups: none. 

<< back